New combo targets stubborn lung cancer cells that survive initial therapy

NCT ID NCT07375316

Recruiting now Disease control Sponsor: Guangdong Association of Clinical Trials Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for people with advanced EGFR-mutated non-small cell lung cancer whose cancer still shows signs of activity (detected by a blood test) after taking the drug osimertinib alone. The trial will test whether adding a second drug, sacituzumab tirumotecan, can improve outcomes. About 120 participants will receive the combination and be monitored for cancer progression and side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University
RECRUITING

Guangzhou, Guangdong, 510080, China
Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences
RECRUITING

Meizhou, Guangdong, 514031, China
Peking University Shenzhen Hospital
RECRUITING

Shenzhen, Guangdong, 518036, China
The First Affiliated Hospital of Shantou University Medical College
RECRUITING

Shantou, Guangdong, 515041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.